Phase I quality control framework for monitoring organ-at-risk dose.

Autor:	Sivabhaskar S; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States of America., Buatti JS; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States of America., Yeh AB; Department of Applied Statistics and Operations Research, Bowling Green State University, Bowling Green, OH, United States of America., Papanikolaou N; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States of America., Roy A; Department of Management Science and Statistics, The University of Texas at San Antonio, San Antonio, TX, United States of America.
Jazyk:	angličtina
Zdroj:	Biomedical physics & engineering express [Biomed Phys Eng Express] 2024 May 10; Vol. 10 (4). Date of Electronic Publication: 2024 May 10.
DOI:	10.1088/2057-1976/ad464d
Abstrakt:	Objective. The aim of this work was to develop a Phase I control chart framework for the recently proposed multivariate risk-adjusted Hotelling'sT2chart. Although this control chart alone can identify most patients receiving extreme organ-at-risk (OAR) dose, it is restricted by underlying distributional assumptions, making it sensitive to extreme observations in the sample, as is typically found in radiotherapy plan quality data such as dose-volume histogram (DVH) points. This can lead to slightly poor-quality plans that should have been identified as out-of-control (OC) to be signaled in-control (IC). Approach . We develop a robust iterative control chart framework to identify all OC patients with abnormally high OAR dose and improve them via re-optimization to achieve an IC sample prior to establishing the Phase I control chart, which can be used to monitor future treatment plans. Main Results . Eighty head-and-neck patients were used in this study. After the first iteration, P14, P67, and P68 were detected as OC for high brainstem dose, warranting re-optimization aimed to reduce brainstem dose without worsening other planning criteria. The DVH and control chart were updated after re-optimization. On the second iteration, P14, P67, and P68 were IC, but P40 was identified as OC. After re-optimizing P40's plan and updating the DVH and control chart, P40 was IC, but P14* (P14's re-optimized plan) and P62 were flagged as OC. P14* could not be re-optimized without worsening target coverage, so only P62 was re-optimized. Ultimately, a fully IC sample was achieved. Multiple iterations were needed to identify and improve all OC patients, and to establish a more robust control limit to monitor future treatment plans. Significance . The iterative procedure resulted in a fully IC sample of patients. With this sample, a more robust Phase I control chart that can monitor OAR doses of new plans was established. (Creative Commons Attribution license.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu